



IMAGE

Docket #: 395D US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Metcalf et al
Serial No.: 09/740,393
Filed: December 18, 2000
For: Purine Derivatives

October 14, 2004

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Applicant hereby files the following documents on this date:

- Supplemental Information Disclosure Statement Under 37 CFR §1.97(B)
- Supplemental Form 1449
- Copies of 7 References listed in Supplemental Form 1449

Respectfully submitted,

10/14/04

David L. Bernstein

David L. Bernstein, Reg No. 31,235
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Telephone: 617-494-0400 Ext. 266
Facsimile: 617-494-0208

Date: October 14, 2004

I hereby certify that this paper is being deposited with the United States Postal Service via First Class Mail under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Alexandria, VA, 22313-1450.

Signed: *Sue Wilson*
Sue Wilson



395D US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Metcalf et al.
USSN : 10/740,393
Filed : December 18, 2000
For : Purine Derivatives

October 14, 2004

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 CFR §1.97(B)

Applicants and their agents/attorneys are aware of the following publications and information, and in accordance with 37 C.F.R. § 1.97 and § 1.98, wish to make them of record. Form PTO-1449 is enclosed.

The Examiner is respectfully requested to initial the space adjacent to each document on the PTO-1449 form and return a copy of the PTO-1449 form to confirm that these documents have been considered by the Examiner and made of record in this application.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited publications.

Authorization is hereby given to charge the \$180.00 fee under 37 CFR 1.17(p), and to charge any deficiency and credit any overpayment, to Deposit Account No. 01-2315. A duplicate copy of this letter is enclosed. Should there be any questions after review of this paper, the Examiner is invited to contact the undersigned at (617) 494-0400 x266.

Respectfully submitted,

Date: 10/14/2004David L. Bernstein

David L. Bernstein, Reg. No. 31,235
ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
(617) 494-0400 Ext. 266

10/20/2004 YPOLITE1 00000038 012315 09740393
01 FC:1806 180.00 DA

I hereby certify that this paper is being deposited with the United States Postal Service "First Class Mail" on the date indicated below and is addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA, 22313-1450.

Date 10/14/04Signed Sue Wilson
Sue Wilson

OCT 18 2004 Form PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO. 395D US

SERIAL NO. 09/740,393

APPLICANT: Metcalf et al.

FILING DATE: 12/18/00

GROUP

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
		4,008,363	2/15/1977	Re et al.			
		6,281,201	8/28/2001	Suhadolnik et al.			
		6,284,748	9/4/2001	Dang et al.			

FOREIGN PATENT DOCUMENTS

Exam Init	Ref Des	Country & Doc. No. (11)	Pub. Date (43)	Name	Class	Sub Class	Translation	
		WO 94/17090	8/4/1994	Gregson et al.			Yes	No

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



SERIAL NO. 09/740,393

FILING DATE: 12/18/00

GROUP

Author, Publication, Pertinent Pages, Date

* a copy of this reference is not provided as it was previously cited by or submitted to the office in the related case,
Patent Application No. _____, filed _____ and relied upon under 35 U.S.C. 120.

DATE CONSIDERED

2